An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center

Dessai, SB; Patil, VijayM; Chakraborty, Santam; Babu, S; Bhattacharjee, Atanu; Nayanar, Sangeetha K; Vikram, Syam; Balasubramanian, Satheesan

doi:10.4103/0019-509x.197743

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete resection of tumour was achieved in 61.5% which is higher compared to the 54.1% of the Norfolk and Norwich Hospital study (12). Similar studies have found that complete resection is signi cantly associated with increased survival and it is one of the main reasons why the ultra-radical approach has been utilized more and more in recent years (13)(14)(15)(16)(17). Incorporating surgery, even for those patients with a greater tumour burden and more disseminated disease who may require more complex procedures and more resources in terms of theater time and hospital stay, seems to be associated with a signi cant prolongation of the patients' overall survival compared with chemotherapy alone (18).…”

Section: Discussionmentioning

confidence: 81%

Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK

Palaiologos

Nikoloudaki

Adedipe

et al. 2024

Minerva Obstet Gynecol

View full text Add to dashboard Cite

BackgroundOvarian cancer is the leading cause of death from gynaecological cancer in the UK. The standard of care is a combination of surgery and chemotherapy. The aim of the treatment is the resection of all macroscopic disease. In selected cases of advanced ovarian cancer this is achieved with ultra-radical surgery. However, NICE encourages further research due to low quality evidence on the safety and e cacy of this extensive surgery. ObjectiveThe aim of this study is to examine the morbidity and survival rates of ultra-radical surgery for advanced ovarian cancer performed in our unit and compare our ndings with the current literature. MethodsThis is a retrospective study of 39 patients diagnosed with stage IIIA-IV ovarian and primary peritoneal cancer who underwent surgery in our unit between 2012 and 2020. The main outcome measures were the perioperative complications, the disease-free survival, the overall survival rate and the recurrence rate. ResultsThe study enrolled 39 patients with stages IIIA-IV who were treated in our unit between 2012 and 2020. 21 patients were at stage III (53.8%) whereas 18 (46.1%) at stage IV. 14 patients underwent primary and 25 secondary debulking surgery. Major and minor complications occurred 17.9% and 56.4% of the patients, respectively. Complete cytoreduction following surgery was achieved in 24 cases (61.5%). The mean and the median survival time were 4.8 years and 5 years, respectively. The mean disease free survival time was 2.9 years while median disease free survival time was 2 years. Age (p=0.028) and complete cytoreduction (p=0.048) were found to be signi cantly associated with survival. Primary debulking surgery was signi cantly associated with lower probability of recurrence (p=0.049). ConclusionAlthough the number of patients is relatively small, our study indicates that ultra-radical surgery in centres with high expertise may result in excellent survival rates with an acceptable rate of major complications. All patients in our cohort were operated by an accredited Gynaecological Oncologist and a Hepatobiliary General Surgeon with a special interest in ovarian cancer. A few cases required input from a Colorectal and a Thoracic Surgeon. We believe that the careful selection of the patients that can bene t from ultra-radical surgery and our model of joint surgery can explain our excellent results. Further research is essential to Page 3/18 establish that ultra-radical surgery has an acceptable rate of morbidity for patients with advanced ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 81%

Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK

Palaiologos

Nikoloudaki

Adedipe

et al. 2024

Minerva Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…The Endometrial cancer is one of the most common cancers in women worldwide and the death rate for this cancer has been increasing with an average increase of 1.4% per year between the years 2005 and 2014 (Miller et al, 2016). Older age, higher stage, grade, tumor size, lymph node status, race, comorbidities, obesity and treatment methods are associated with lower endometrial cancer survival (Dessai et al, 2016;Bregar et al, 2017;Nicholas et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Accelerated Failure Time Models with Applications to Endometrial Cancer Survival Data

Tripathy

Swain

Sarangi

et al. 2023

JRSS

View full text Add to dashboard Cite

The objective of this study is to determine the significant predictors of endometrial cancer using accelerated failure time models (AFTM). We have demonstrated the applications of AFTM viz. Exponential, Weibull, Log-normal, Log-logistic, Gompertz, Gamma and Generalized Gamma AFTM, as an alternative of Cox proportional hazard model. Data for the analysis was collected from Acharya Harihar Post Graduate Institute of Cancer (AHPGIC), Cuttack, Odisha during the period 2016–20. Based on the lowest Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) value, the Weibull AFTM has been chosen as the best fitted AFT model. The predictors such as age, comorbidity, tumor size, isolated para-aortic and adnexa have been found as significant predictors (p-value < 0.05) to explain the survival of endometrial cancer patients. Hence, by optimizing different treatments, based on such prognostic factors plays an important role in managing endometrial cancer at an early stage.

show abstract

Carboplatin/paclitaxel

2017

Reactions Weekly

View full text Add to dashboard Cite

An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center

Abstract: Optimal cytoreduction may improve PFS in advanced ovarian cancer patients and needs to be done even if it mandates an ultra-radical surgery.

Cited by 6 publications

References 0 publications

Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK

Ultra-radical surgery for advanced ovarian cancer: a retrospective cohort study in a tertiary referral cancer center in the UK

Accelerated Failure Time Models with Applications to Endometrial Cancer Survival Data

Carboplatin/paclitaxel

Contact Info

Product

Resources

About